Answers are grounded in this paper and cite their sources.
Using examples from recent FDA regulatory proceedings, Jonas Hines and colleagues critique the medical device premarket review and identify eight weaknesses in the process that should be remedied.
No takes yet. Share an insight, caveat, or question.
Hines et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: